BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (see an example) and are provided with free text boxes to elaborate on their assessment. These free text comments are reproduced below. This paper was submitted to the THORAX but declined for publication following peer review. The authors addressed the reviewers' comments and submitted the revised paper to BMJ Open where it was re-reviewed and accepted.
Unfortunately, the authors have not explained on what basis the primary sub-phenotype of emphysema was assessed (present or absent) other than by 2 "experienced" radiologists. As most of the conclusions from the study are based on this distinction, it is a concern that there is no objective (or even semi-quantitative) basis on which to define this phenotype.
Other concerns are 1. differences in follow up period with respect to outcomes 2. multiple comparisons with no correction of the P value to allow for this 3. the asthma phenotype and just how many people were defined as asthma based on the many possible criteria. 4. numerous grammatical errors 5. just what new findings were found given the existing literature.
-The manuscript received two reviews at The THORAX but the other reviewer have declined to make the reviews public. Please contact BMJ Open editorial office for any further information.
VERSION 1 -AUTHOR RESPONSE

Comments to the Author
This study is a retrospective observational study that is more of a case series where patients who have undergone spirometry (with reversibility) and CT have been identified over a specified time period. The patients have been sub-phenotyped and then various characteristics and outcomes compared.
A: We diagnosed emphysema by the assessments of two radiologists because of following reasons.
1. Definition of emphysema by CT pixels (under -950 HU) is changed by CT to CT even if settings are standardized. CT pixels sometimes cannot discriminate bullae or over-inflation. We used CT pixels in previous studies, but diagnosis of emphysema is more accurate by the assessment of radiologists.
2. We hoped that our findings would be useful for daily practices of every physicians, but definition of emphysema by CT pixels cannot be applied to daily use.
3. There are many publications in which emphysema was defined by assessment of radiologists, not use CT pixels. We added following sentence in the HRCT section in the METHOD.
"The presence of emphysema was defined as well-demarcated areas of decreased attenuation in comparison with contiguous normal lung and marginated by a very thin or no wall with upper zone predominance."
Other concerns are 1. differences in follow up period with respect to outcomes A: It is true that follow up periods of asthma subgroups were longer than other groups. One possible reason would be that mean survival time were longer in asthma patients.
2. multiple comparisons with no correction of the P value to allow for this A: If there are more specific points, we could reevaluate the statistics.
3. the asthma phenotype and just how many people were defined as asthma based on the many possible criteria.
A: We used GINA guidelines and added it in the reference.
numerous grammatical errors
A: We corrected them as much as possible.
5. just what new findings were found given the existing literature.
A: Current guidelines of COPD does not emphasize differential diagnosis. The patients with CAO are frequently diagnosed just as COPD. In addition, mortalities of asthma were significantly improved by the use of inhaled corticosteroids. This study showed the impact of emphysema on the prognosis of CAO and compared prognosis of asthma and COPD after ICS become first line therapy for asthma.
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THE STUDY
As the authors discussed, this was a retrospective observational study with all patients' data collected from one single center in Japan. The overall study design and representation of actual patients population are therefore limited by the nature of data used to address the research question of interest.
The statistical methods described in the analysis section are generally appropriate for this type of data, but need to be improved to best address the research objectives.
There are two important factors to classify all subjects with CAO: disease symptoms (COPD/asthma/others) and presence of emphysema (yes/no). The regression analysis should start with two independent factors, with their interaction being tested in the model. A consistent modelling approach should be used for all outcomes including overall survival and by subgroups, as well as the causes of mortality. Due to the differences between patients subgroups that may be related to prognostic factors, the main conclusions should focus on properly adjusted regression analysis rather than the unadjusted results (if conducted). RESULTS & CONCLUSIONS The prevalence of phenotypes in patients with CAO are better presented in Figure 1 as two independent factors. All patients may be first classified by disease symptoms (COPD/asthma/others) and then subdivided by the presence of emphysema with associated proportions. This way of presentation is more in line with the initial hypothesis that clinical significance of emphysema in the prognosis of the patients with CAO is not limited to COPD, but other respiratory disease such as asthma.
Both n and % should be given to categorical variables in Table 1 , and the overall p-value from the analysis of variance cannot be directly related to any further comparisons between subgroups as presented in the RESULTS on Patient Characteristics. More numerical results should be added to support these statements.
The main results on the primary endpoint, overall survival, are based on Kaplan-Meier survival curves and unadjusted log-rank test. This is not considered appropriate. Figure 2 should not exclude other RD if all patients' data have been included in adjusted Cox regression analysis, which results are presented in supplementary table instead. No standard numerical outputs are presented in any of the survival curves.
Differences in causes of mortality were analyzed by Chi-square test, which is not appropriate with some very small cells presented in Table 3 . Note that the p-value was not statistically significant at 5% level, but claimed as significant differences among the subgroups in the RESULTS. Majority of the lung cancer patients are in the COPD with emphysema subgroup. Therefore, the analysis using all 1272 patients with only the presence of emphysema as an independent risk factor in logistic regression model is not considered appropriate. Also, can the authors explain why only lung cancer was investigated but not other causes of mortality?
VERSION 2 -AUTHOR RESPONSE
Commemt 1: There are two important factors to classify all subjects with CAO: disease symptoms (COPD/asthma/others) and presence of emphysema (yes/no). The regression analysis should start with two independent factors, with their interaction being tested in the model. A consistent modelling approach should be used for all outcomes including overall survival and by subgroups, as well as the causes of mortality. Due to the differences between patients subgroups that may be related to prognostic factors, the main conclusions should focus on properly adjusted regression analysis rather than the unadjusted results (if conducted).
Answer: We classified disease symptoms (COPD/asthma/others) and presence of emphysema (yes/no) throughout the text. We first analyzed overall survival for COPD/asthma/others adjusted by possible variables (revised supplementary Table 3 ). We compared survivals of COPD and asthma subgroups (with or without emphysema) by log rank test and HR were calculated by regression analysis adjusted for proper variables (supplementary Table 4) Comment 2:
The prevalence of phenotypes in patients with CAO are better presented in Figure 1 as two independent factors. All patients may be first classified by disease symptoms (COPD/asthma/others) and then subdivided by the presence of emphysema with associated proportions. This way of presentation is more in line with the initial hypothesis that clinical significance of emphysema in the prognosis of the patients with CAO is not limited to COPD, but other respiratory disease such as asthma.
Answer: We changed Figure 1 as recommended.
Comment 3: Both n and % should be given to categorical variables in Table 1 , and the overall p-value from the analysis of variance cannot be directly related to any further comparisons between subgroups as presented in the RESULTS on Patient Characteristics. More numerical results should be added to support these statements.
Answer: 1) We changed Table 1 as recommended. 2) There was a typographical error in the percentage of female in the text, and we corrected it (Table  1 was correct). 3) We have data of Tukey's multiple comparison test for the comparisons between subgroups, but there are 15 comparison sets for each variables. Since the details of differences in age and smoking history are not essential for the context of text, we simply deleted them. Table 1 . In total, 176 (13.8 %) patients were female, and 1131 (88.9 %) patients had a smoking history. All of COPD patients and all of the patients with emphysema had smoking histories. COPD patients with emphysema had the lowest BMI."
Comment 4:
The main results on the primary endpoint, overall survival, are based on Kaplan-Meier survival curves and unadjusted log-rank test. This is not considered appropriate. Table 3 , we showed that COPD and asthma had different overall survivals with adjusted variables. 4) Differences in mortalities of subgroups with or without emphysema in COPD and asthma were tested by log-rank test, and we added adjusted hazard ratio evaluated by Cox regression analysis as supplementary Table 4 .
Comment 5: Differences in causes of mortality were analyzed by Chi-square test, which is not appropriate with some very small cells presented in Table 3 . Note that the p-value was not statistically significant at 5% level, but claimed as significant differences among the subgroups in the RESULTS. Majority of the lung cancer patients are in the COPD with emphysema subgroup. Therefore, the analysis using all 1272 patients with only the presence of emphysema as an independent risk factor in logistic regression model is not considered appropriate. Also, can the authors explain why only lung cancer was investigated but not other causes of mortality?
Answers: 1) We agree that Chi-square test was not appropriate for the analysis. We recalculated by Fisher-Freeman-Halton test for the analysis of mortality causes, and changed Table 3. 2) We did not analyze each subgroup difference in mortality. Death by lung cancer is accumulated in COPD with emphysema in Table 3 , but more important information would be the frequency of de novo lung cancer during observation period (including alive patients) which is not presented in Table 3 . Frequencies of de novo lung cancer during observation period were as follows. COPD with emphysema 38/517 (7.7%) COPD without emphysema 5/104 (4.8%) Asthma with emphysema 4/178 (2.2%) Asthma without emphysema 2/168 (1.1%) Other RD with emphysema 8/128 (6.25%) Other RD without emphysema 3/176 (1.7%) (In revised text we excluded lung tumor only diagnosed by CT without evidence of cytology or histology, they all in patients with COPD with emphysema). To answer the anticipation that lung cancer was accumulated in COPD, we added COPD, asthma, and other RD as variables to explain risk of lung cancer by multiple logistic regression analysis with Firth's bias reduction. (Emphysema were not significant by Cox regression analysis, p = 0.07. Since Cox regression uses some estimation, we used Firth's bias reduction to obtain exact P value). Refference: Bias Reduction of Maximum Likelihood Estimates. Firth D, Biometrika, 1993;80(1):27-38. After recalculation, we found that emphysema and asthma were positive and negative risk factors for de novo lung cancer. Therefore, we changed text and Table 4 . 3) We investigated only incidence of de novo lung cancer, not other malignancy or infectious disease, by following reasons. A. We followed up chest X-ray and/or CT for all patients, and we could detect de novo lung cancer. However, we could not check every other de novo malignancies, and we might miss other malignant disease (for example, occult cancer in prostate or thyroid, or early gastric cancer, etc). B. We could not detect incidences of de novo respiratory infectious diseases because mild infectious diseases might have been treated in other primary clinics or spontaneously improved. (If they died by infectious diseases we could count them because they were hospitalized. Otherwise, they were counted as unknown.)
